Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) ROC (Joel Greenblatt) %: 0.00% (As of . 20)


XTUN:SIPHA Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
12 GF Score
Price TND4.00
! 1 Warning Sign
View Full Analysis

What is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC (Joel Greenblatt) %?

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA 12 ROC (Joel Greenblatt) % is 0.00% as of . 20. GuruFocus rates XTUN:SIPHA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % or its related term are showing as below:

XTUN:SIPHA's ROC (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 11.45
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T  (XTUN:SIPHA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC (Joel Greenblatt) % Related Terms


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC (Joel Greenblatt) % Chart

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Annual Data
Trend
ROC (Joel Greenblatt) %

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Semi-Annual Data
ROC (Joel Greenblatt) %

XTUN:SIPHA vs BIEI, PTXTQ, INQD: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % falls into.


XTUN:SIPHA
12GF Score
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Societe des Industries Pharmaceutiques de Tunisie-S I PHA T for the quarter that ended in . 20 can be restated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a ROC (Joel Greenblatt) % of 0.00% as of . 20. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current ROC (Joel Greenblatt) % is 0.00%. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC (Joel Greenblatt) % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROC (Joel Greenblatt) % is 11.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current ROC (Joel Greenblatt) % of 0.00%. The current ROC (Joel Greenblatt) % is 0.00%. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current ROC (Joel Greenblatt) % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Business Description

Address Fondouk Choucha, Ben Arous, TUN, 2013
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score

Get the complete analysis for XTUN:SIPHA

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

TND4.00
Price